Preclinical to Phase Montis Biosciences is a preclinical-stage biopharma planning to initiate two Phase 1 trials in 1H 2026, indicating potential timelines for partnerships, collaborations, and co-development discussions aligned with early clinical development opportunities.

C1q Platform Value Lead program MB01 targets C1q functions beyond classical pathway inhibition, representing an opportunity to license or co-develop novel complement-related therapeutics for neuroinflammatory and autoimmune indications with potentially differentiated mechanisms.

LUSC Opportunity Second program MB02 targets CD93 in lung squamous cell carcinoma with best-in-class potential, suggesting target-focused partnerships or strategic licensing deals in oncology and inflammation-driven tumor microenvironment therapies.

Investor Backing Strong investor syndicate including Droia Ventures, Pfizer Ventures, Polaris Innovation Fund, ALSA Ventures and VIB signals credibility and potential for strategic collaboration, non-dilutive support, and co-development discussions with large pharma.

Partnership Readiness Recent preclinical data releases and ongoing platform-driven discovery, combined with a relatively lean team, create receptive conditions for early-outlicensed deals, research collaborations, and sponsored research engagements with pharma and biotech partners.